Spero soars as UTI drug trial with partner GSK stops after early success
Shares of drug developer Spero Therapeutics SPRO.O jumps 241.6% to $2.33 premarket
Co and partner GSK GSK.L to stop trial of experimental urinary tract drug tebipenem HBr due to early success after it met the main goal of a late-stage study
The decision comes after a recommendation from an independent committee that completed a pre-specified interim analysis of data from 1,690 patients enrolled in the trial
In the trial, the drug showed it was at least as good as an existing intravenous treatment in hospitalized adult patients
As of last close, SPRO stock down 33.8% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Why SanDisk Stock Could Soar to $4,000?

AI Chip Sector Adds Heavyweight Player, Nvidia Rival Cerebras Plans to List Next Week, Targeting Largest US IPO of the Year

Trump Administration Brokers. Intel and Apple Reach Chipmaking Agreement, Shares Surge More Than 13%

Navitas Stock’s AI Data Center Pivot: Up 88% YTD—Is NVTS Stock Still a Buy?

SK Hynix Capacity Hits Zero: Tech Giants Offer to Fund Factories Amid AI Chip Shortage

Tradingkey








